Cardiff Oncology, Inc. (CRDF)
| Market Cap | 125.28M |
| Revenue (ttm) | 688,000 |
| Net Income (ttm) | -43.01M |
| Shares Out | 51.13M |
| EPS (ttm) | -0.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 481,511 |
| Open | 2.500 |
| Previous Close | 2.500 |
| Day's Range | 2.443 - 2.560 |
| 52-Week Range | 1.150 - 6.420 |
| Beta | 1.93 |
| Analysts | Strong Buy |
| Price Target | 9.33 (+280.82%) |
| Earnings Date | Nov 7, 2024 |
About CRDF
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufact... [Read more]
Financial Performance
In 2023, Cardiff Oncology's revenue was $488,000, an increase of 26.42% compared to the previous year's $386,000. Losses were -$41.47 million, 7.07% more than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for CRDF stock is "Strong Buy." The 12-month stock price forecast is $9.33, which is an increase of 280.82% from the latest price.
News
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC -
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated metastatic colorectal cancer, potentially opening a massive market with an estimated $567 million to $3.78 billion in annual US sal...
Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point
Cardiff Oncology, Inc. results from the phase 2 CRDF-004 study, using onvansertib + Folfiri + bevacizumab for the treatment of patients with RAS-mutant mCRC, expected in the 2nd half of 2024. The glob...
Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript
Cardiff Oncology, Inc. (NASDAQ:CRDF) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Of...
Cardiff Oncology to Present at the Jefferies Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancer...
Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data
Cardiff Oncology's Onvansertib is a first-in-class oral PLK1 inhibitor that targets difficult-to-treat cancers such as mCRC, mPDAC, SCLC, and TNBC. Onvansertib's promising early data suggest that it o...
Cardiff Oncology to Present at Upcoming Investor Conferences in May
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancer...
Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript
Cardiff Oncology, Inc. (NASDAQ:CRDF) Q1 2024 Results Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Execut...
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated m...
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m.
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vasculariz...
Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Cardiff Oncology is focused on developing a drug for colorectal cancer and pancreatic cancer, with promising early activity shown in colorectal cancer patients. The company is now focused on moving th...
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of canc...
Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript
Cardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
- First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite -
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
- New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients -
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
- Phase 2 trial in patients with RAS-mutated mCRC will evaluate onvansertib plus SoC versus SoC alone in the first-line setting -
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance...
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
- Management will hold a conference call on Thursday, February 29 at 4:30 p.m. ET/1:30 p.m.
Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
- Findings from the Phase 1b portion of company's Phase 1b/2 study in second-line KRAS-mutated mCRC highlight the safety and promising efficacy of onvansertib in combination with standard-of-care - - ...
Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference
SAN DIEGO , Nov. 20, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...
Cardiff Oncology, Inc. (CRDF) Q3 2023 Earnings Call Transcript
Cardiff Oncology, Inc. (NASDAQ:CRDF) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Kiki Patel - IR, Gilmartin Group Mark Erlander - CEO Jamie Levine - CFO Conferen...
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update
- Advance to first-line RAS-mutated metastatic colorectal cancer (mCRC) for lead program based on positive clinical and preclinical data and guidance from FDA - - Expanded relationship with Pfizer, w...
Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update
- Management will hold a conference call on Thursday, November 2 at 4:30 p.m. ET/1:30 p.m.
Costco share fall following results, while Cardiff Oncology and MillerKnoll shares soar, and more moving stocks
Cardiff Oncology Inc. CRDF, +0.62% shares surged 32% on favorable data from two cancer drug trials — metastatic pancreatic ductal adenocarcinoma and small cell lung cancer treatment.